Matrixyl vs Copper Peptides: Which Has Better Evidence?

Start with our pillar guide: Argireline vs Matrixyl: Mechanisms, Trials and Which to Use, or browse all Reviews & Comparisons articles.

Short answer: In Matrixyl vs copper peptides, Matrixyl has better human evidence. Palmitoyl pentapeptide-4 (Matrixyl) has a 93-person, 12-week placebo-controlled trial run by Procter & Gamble plus a 21-person independent trial. GHK-Cu (copper peptide) has strong cell and animal data but almost no indexed clinical trials. Evidence: limited (Matrixyl); lab/animal only (topical GHK-Cu).

Most people expect the opposite result. Copper peptides get more attention, have the longer research history and come with a better origin story. But when we went looking for published, peer-reviewed facial trials, the evidence for the two ingredients turned out to be lopsided.

This article compares them on mechanism, human trials, skin penetration and labeling, and covers how to use both. For background, see our pillar guides to copper peptides for skin and to the main peptide ingredients in skincare.

Key takeaways

• Palmitoyl pentapeptide-4 has 2 published randomized, placebo-controlled trials: one funded by its manufacturer (n=93, 12 weeks) and one small independent study (n=21, 8 weeks).
• GHK-Cu stimulates collagen in cell culture and in rat wounds. A 2025 review noted a "surprising absence of clinical studies" for topical GHK-Cu.
• Matrixyl 3000 is a different product from the original Matrixyl. Neither of the trials above tested it.
• Through intact human skin, almost no GHK-Cu got through in a lab test. Matrixyl 3000's peptides have been detected in the outer skin layer of 3 volunteers.
• No study has tested the two ingredients together, so there is no evidence of either a conflict or a benefit.

What are Matrixyl and copper peptides?

"Matrixyl" and "copper peptide" are trade or common names. The ingredient list on the jar uses INCI names (the standardized International Nomenclature of Cosmetic Ingredients). The EU's CosIng database lists them as follows:

• Original Matrixyl: PALMITOYL PENTAPEPTIDE-4, also written pal-KTTKS. CosIng function: skin conditioning, miscellaneous.
• Matrixyl 3000: PALMITOYL TRIPEPTIDE-1 (Pal-GHK) plus PALMITOYL TETRAPEPTIDE-7 (Pal-GQPR). Both are classed as skin conditioning.
• Copper peptide: COPPER TRIPEPTIDE-1, the copper complex of tripeptide-1 (GHK). Classed as skin conditioning.

Matrixyl 3000 contains palmitoyl tripeptide-1, which is the GHK sequence with a fatty acid attached. So one of its 2 peptides is a close relative of the peptide in copper peptides, just without the copper.

A widely cited review sorts cosmetic peptides into 4 classes: signal, enzyme-inhibitor, neurotransmitter-inhibitor and carrier peptides (Gorouhi & Maibach, 2009). Pal-KTTKS is usually described as a signal peptide, meaning a fragment meant to "tell" fibroblasts to make more matrix proteins. GHK-Cu is the standard carrier peptide, meaning it delivers copper, a cofactor for enzymes involved in wound repair.

Does Matrixyl (palmitoyl pentapeptide-4) work in human trials?

Yes, modestly. A 93-person, 12-week P&G split-face trial and a 21-person independent trial both found wrinkle improvements versus placebo.

The P&G split-face trial

In a 12-week, double-blind, placebo-controlled, randomized split-face trial, 93 Caucasian women aged 35–55 applied a moisturizer with 3 ppm (0.0003%) pal-KTTKS to one side of the face and placebo to the other (Robinson et al., 2005). The peptide side showed significant improvement in wrinkles and fine lines compared with placebo, judged by both image analysis and expert graders, and was well tolerated. Procter & Gamble ran the study. Evidence: limited.

The paper has been cited about 180 times, and we didn't find an independent replication at the same scale. In a split-face design, each person acts as their own control, which removes much of the person-to-person variation. It also means the trial measured a difference between 2 sides of one face, not a dramatic overall change.

The small independent trial

In an 8-week, double-blind RCT of 21 Indonesian women aged 26–55, palmitoyl pentapeptide-4 improved crow's feet more than both acetyl hexapeptide-3 (Argireline) and placebo (Aruan et al., 2023). The authors reported no conflicts of interest. They called it an initial study that needs more participants and a longer follow-up. Evidence: early / preliminary.

We compare those two directly in Argireline vs Matrixyl.

Why the label is "limited," not "moderate"

On paper, 2 human controlled trials point the same way. But 1 is manufacturer-funded and the other has 21 participants spread across 3 groups. Together that is a reasonable signal but not a strong one.

A lab detail helps the case: in a skin homogenate assay, pal-KTTKS stayed stable against skin proteases for up to 8 hours (Errante et al., 2021). One author worked part-time for Espikem, a peptide company. Evidence: lab only.

Do copper peptides (GHK-Cu) work in human trials?

The evidence is thin. GHK-Cu has strong lab and animal data but almost no indexed, controlled facial trials.

The lab and animal record is strong

In fibroblast cultures, GHK-Cu stimulated collagen synthesis starting at 10⁻¹²–10⁻¹¹ M, with a maximum at 10⁻⁹ M, and the effect didn't depend on cell number (Maquart et al., 1988). In rat wound chambers, injected GHK-Cu caused dose-dependent increases in collagen, glycosaminoglycans, DNA and protein, and raised type I and III collagen mRNA. A control tripeptide had no effect (Maquart et al., 1993). Evidence: lab / animal only.

Newer lab work continues the pattern. In a study by 2 ingredient manufacturers, GHK-Cu combined with low-molecular-weight hyaluronic acid at a 1:9 ratio raised collagen IV 25.4-fold in fibroblasts and 2.03-fold in ex vivo skin (Jiang et al., 2023). Evidence: lab only, manufacturer-funded.

The clinical gap

A 2015 review by authors from Skin Biology, a copper peptide company, reports that plasma GHK falls from about 200 ng/mL at age 20 to about 80 ng/mL at 60 (Pickart et al., 2015). The review also summarizes several facial studies: a 12-week study in 71 women, an eye cream study in 41 women compared with placebo and vitamin K, and a study in 67 women aged 50–59. We couldn't find any of these as full, indexed, peer-reviewed papers.

A 2025 review of GHK, with no declared conflicts, reached the same conclusion. Cellular studies support an anti-wrinkle effect, but there is a "surprising absence of clinical studies" for GHK-Cu and Pal-GHK (Mortazavi et al., 2025; a narrative review with about 12 citations so far. Evidence: limited.). Evidence: lab / animal only for indexed topical data.

To be precise about the gap: an NPR report described topical copper serums as "studied in human trials," mostly "small trials funded by the cosmetic industry" (Stone, NPR, 2026). Both statements can be true. Some industry trials exist, but they haven't reached the indexed literature where we and others can check them. The same NPR report covers people injecting GHK-Cu bought from grey-market sellers. It notes that no published human studies show this is safe or effective, and that GHK-Cu isn't an approved drug. Our article covers topical use only.

Penetration: does either one get in?

Only partly. Both reach the outer skin layer in lab or volunteer studies, but neither has been shown to reach the dermis from a normal cream.

Both ingredients face the same basic problem. Peptides are large, mostly water-loving and carry electrical charges, which makes delivery through skin hard. Skin enzymes can also break them down. One review concluded that most anti-wrinkle peptides "might not reach their targets in the skin at right concentrations" without help, although permeation enhancers, microneedles or nanocarriers can raise delivery (Mortazavi & Moghimi, 2022). We cover this in more depth in our explainer on whether peptides absorb into skin.

GHK-Cu: - Its log D (a measure of oil vs water preference) is −2.38 to −2.49 at pH 4.5–7.4, which means it is highly hydrophilic (water-loving). It stayed stable for 2 weeks at 60 °C in that pH range but broke down under basic and oxidative conditions (Badenhorst et al., 2016). - Through intact human skin, "almost no peptide or copper permeated" in 9 hours. After microneedle pretreatment, 134 nmol of peptide and 705 nmol of copper got through (Li et al., 2015). - Another lab study used a 0.68% aqueous solution applied in excess. About 136 µg/cm² of copper permeated dermatomed (thinly sliced) human skin over 48 hours (Hostynek et al., 2011). That study measured copper, not the intact peptide. - A 2025 review notes that skin transport of liposome-encapsulated GHK-Cu has "received little attention" (Ogórek et al., 2025).

Matrixyl 3000: - In 3 healthy women, palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 from a serum were detected throughout every layer of the stratum corneum (the outermost layer of skin) at 0.5, 2 and 5 hours. Levels decreased with depth and didn't change significantly with longer exposure (Trzaska et al., 2026). The peptides sat on the outer surfaces of cells, between them rather than inside. Authors included University of Nottingham researchers and No7/Boots employees, the sample was n=3, and the 2026 paper has no citations yet. Evidence: early / preliminary.

The palmitoyl tail is meant to make these peptides more fat-soluble, and the Trzaska data fit that idea. But reaching the stratum corneum doesn't show that they reach the fibroblasts in the dermis.

For contrast, Argireline: the one direct penetration measurement for a neurotransmitter-type peptide found 0.22% of a 10% acetyl hexapeptide-8 cream in the stratum corneum of human cadaver skin, 0.01% in the epidermis and none in the dermis after 24 hours (Kraeling et al., 2015). Neither Matrixyl nor GHK-Cu has an equivalent dermis measurement from a normal cream on intact human skin.

Is Matrixyl the same as Matrixyl 3000?

No. Matrixyl is palmitoyl pentapeptide-4; Matrixyl 3000 is a blend of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 with different evidence.

Product pages often blur this distinction. Both published Matrixyl trials above tested palmitoyl pentapeptide-4. Matrixyl 3000 is a different blend, and the only indexed human data we found for it is the 3-person penetration study. Neither paper tested its effect on wrinkles. The 2025 GHK review specifically lists Pal-GHK, one of its 2 peptides, among the ingredients lacking clinical studies (Mortazavi et al., 2025).

This may explain a pattern in skincare forums. Some users say Matrixyl 3000 did nothing visible for them, while others credit a Matrixyl plus Argireline serum. Anecdotes can't settle the question. But "Matrixyl" on a label could mean either product, and only one of them has been tested in a published wrinkle trial.

Matrixyl vs copper peptides: comparison table

Can you use Matrixyl and copper peptides together?

There is no published combination trial and no study showing a conflict between them. Anyone claiming they boost each other, or cancel each other out, is going beyond the evidence.

Since they work through different proposed mechanisms (signaling vs copper delivery), there's no theoretical reason they can't share a routine. If your Matrixyl product is the 3000 version, though, you'd be applying 2 forms of the GHK sequence, and we have no data on whether that adds anything. A simple approach is to apply them at different times of day or on alternate days, then judge after at least 8–12 weeks, which matches the length of the published trials.

A common question is which peptide to buy first. By published evidence alone, a product that lists palmitoyl pentapeptide-4 by INCI name is the better-documented choice. That reflects the available data. It doesn't guarantee results.

How do Matrixyl and copper peptides compare to retinoids?

Retinoids have far more human evidence than either peptide and remain the benchmark topical for wrinkles.

Retinoids have far more evidence than either peptide. A review of retinoid clinical trials summarizes decades of efficacy and safety data (Mukherjee et al., 2006). In one 24-week RCT of 36 elderly people (mean age 87), 0.4% retinol applied to the arms up to 3 times a week changed fine wrinkle scores by −1.64, compared with −0.08 for the vehicle cream. It also raised glycosaminoglycans and procollagen I (Kafi et al., 2007). The funder isn't reported in our source notes. Evidence: well-established (retinoids as a class).

The tradeoff is tolerability, and retinoids cause more irritation for many people. Peptides are often used alongside retinoids or as gentler options. If you're weighing prescription retinoids, talk to a dermatologist.

Where the evidence stops

• No head-to-head trial of Matrixyl and GHK-Cu exists, and no study has tested them together.
• No indexed clinical trial of topical GHK-Cu or Matrixyl 3000 for wrinkles was found. The facial studies described by the copper peptide company aren't available as full papers.
• The Matrixyl evidence is thin. It rests on 1 manufacturer trial and 1 trial of 21 people, with no long-term data beyond 12 weeks.
• Dermal delivery is unproven for both ingredients in intact human skin at cosmetic concentrations.
• Most products don't list concentrations, so you usually can't tell whether a product matches the 3 ppm level tested in the trial.

FAQ

Is Matrixyl or copper peptide better for wrinkles? Only palmitoyl pentapeptide-4 (Matrixyl) has published, placebo-controlled human trials showing wrinkle improvement (Robinson et al., 2005; Aruan et al., 2023). GHK-Cu has strong lab and animal data but lacks indexed clinical trials (Mortazavi et al., 2025). We don't know which works better because no study has compared them.

Is Matrixyl 3000 the same as Matrixyl? No. Matrixyl is palmitoyl pentapeptide-4, and Matrixyl 3000 is palmitoyl tripeptide-1 plus palmitoyl tetrapeptide-7. The published wrinkle trials tested the original Matrixyl.

Can I use Matrixyl and copper peptides together? No study has tested the combination, so there is no evidence of a conflict or of extra benefit. Many people use them in the same routine, often at separate times of day.

Why did Matrixyl 3000 do nothing for me? We can't say for any one person. Matrixyl 3000 hasn't been tested in a published wrinkle trial, and its peptides were detected in the stratum corneum but not shown to reach deeper skin (Trzaska et al., 2026). The published trials ran 8–12 weeks, so a shorter trial period also might not show changes.

Which peptide should I buy first? On published human evidence alone, palmitoyl pentapeptide-4 has the stronger record. Check the INCI list for that exact name rather than relying on the word "Matrixyl" on the front of the bottle.

Are copper peptides or Matrixyl better than retinol? Retinoids have much more clinical evidence, including RCTs showing wrinkle and collagen changes (Kafi et al., 2007; Mukherjee et al., 2006). Peptides are milder but less proven. A dermatologist can help you choose based on your skin.

References

1. Robinson LR, et al. Int J Cosmet Sci, 2005. Double-blind, placebo-controlled, randomized split-face trial; n=93 women aged 35–55; 12 weeks; 3 ppm palmitoyl pentapeptide-4; funded by Procter & Gamble. https://pubmed.ncbi.nlm.nih.gov/18492182/
2. Aruan RR, et al. J Clin Aesthet Dermatol, 2023. Double-blind RCT; n=21 women aged 26–55; 8 weeks; acetyl hexapeptide-3 vs palmitoyl pentapeptide-4 vs placebo; no conflicts of interest reported. https://pubmed.ncbi.nlm.nih.gov/36909866/
3. Trzaska AH, et al. Int J Pharm, 2026. In vivo stratum corneum penetration of Matrixyl 3000 peptides; n=3 women; University of Nottingham and No7/Boots authors. https://pubmed.ncbi.nlm.nih.gov/42790608/
4. Errante F, et al. J Pharm Biomed Anal, 2021. In vitro skin homogenate protease stability assay; 1 author part-time at Espikem. https://pubmed.ncbi.nlm.nih.gov/33281001/
5. Maquart FX, Pickart L, et al. FEBS Lett, 1988. In vitro fibroblast culture study of GHK-Cu and collagen synthesis. https://pubmed.ncbi.nlm.nih.gov/3169264/
6. Maquart FX, et al. J Clin Invest, 1993. Animal study; rat wound chambers with injected GHK-Cu. https://pubmed.ncbi.nlm.nih.gov/8227353/
7. Pickart L, et al. Biomed Res Int, 2015. Narrative review by Skin Biology company authors. https://pubmed.ncbi.nlm.nih.gov/26236730/
8. Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Bioimpacts, 2025. Review of GHK and its derivatives; no conflicts declared. https://pubmed.ncbi.nlm.nih.gov/39963574/
9. Hostynek JJ, Dreher F, Maibach HI. Inflamm Res, 2011. In vitro human skin penetration of copper from 0.68% copper tripeptide; 48 hours. https://pubmed.ncbi.nlm.nih.gov/20721598/
10. Li H, et al. Pharm Res, 2015. In vitro human skin permeation of GHK-Cu, with and without microneedle pretreatment; 9 hours. https://pubmed.ncbi.nlm.nih.gov/25690343/
11. Badenhorst T, et al. Pharm Dev Technol, 2016. Physicochemical and stability characterization of GHK-Cu (lab study). https://pubmed.ncbi.nlm.nih.gov/25384620/
12. Mortazavi SM, Moghimi HR. "Skin permeability, a dismissed necessity for anti-wrinkle peptide performance." Int J Cosmet Sci, 2022. Review. https://pubmed.ncbi.nlm.nih.gov/35302659/
13. Gorouhi F, Maibach HI. Int J Cosmet Sci, 2009. Review of topical peptides and their 4 functional classes. https://pubmed.ncbi.nlm.nih.gov/19570099/
14. Kafi R, et al. Arch Dermatol, 2007. RCT; n=36 elderly participants (mean age 87); 24 weeks; 0.4% retinol vs vehicle. https://pubmed.ncbi.nlm.nih.gov/17515510/
15. Mukherjee S, et al. Clin Interv Aging, 2006. Review of the clinical efficacy and safety of retinoids. https://pubmed.ncbi.nlm.nih.gov/18046911/
16. Ogórek K, et al. Molecules, 2025. Review of GHK-Cu delivery and permeation. https://pubmed.ncbi.nlm.nih.gov/39795193/
17. Jiang F, et al. J Cosmet Dermatol, 2023. In vitro and ex vivo study of GHK-Cu plus low-molecular-weight hyaluronic acid; authors from manufacturers Bloomage and Peptites. https://pubmed.ncbi.nlm.nih.gov/37062921/

Other sources (not efficacy evidence): 18. Kraeling ME, Zhou W, Wang P, Ogunsola OA. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol. 2015. In vitro, human cadaver and hairless guinea pig skin, 10% O/W emulsion, 24 h; US FDA authors. https://pubmed.ncbi.nlm.nih.gov/24754410/

• European Commission CosIng database: entries for COPPER TRIPEPTIDE-1, PALMITOYL PENTAPEPTIDE-4, PALMITOYL TRIPEPTIDE-1 and PALMITOYL TETRAPEPTIDE-7. https://ec.europa.eu/growth/tools-databases/cosing/
• Stone W. "The copper peptide trend has gone from creams to injections — ahead of the science." NPR Morning Edition, September 7, 2026. News report. https://www.npr.org/2026/09/07/nx-s1-5955552/copper-peptides-skin-aging-health-safe

Disclosure: This article contains no affiliate links. It summarizes published research for general education only and isn't medical advice. Talk to a dermatologist or other qualified clinician before starting prescription treatments, and before using any injectable peptide.

For educational purposes only; not medical advice. See our disclaimer and research method.